drugset / Trial / NCT04356222

Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

NCT04356222

Phase 4 Unknown 30 enrolled Hui Bu
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to observe the clinical efficacy and safety of Durvalumab combined with intrathecal chemotherapy in non-small cell lung cancer with leptomeningeal metastasis

Timeline

Start
2020-06
Primary completion
2023-06
Completion
2023-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Durvalumab Monoclonal antibody 10 mg/kg Intravenous
Subject Methotrexate Small molecule Other

Indications